← Back to Search

Janus Kinase Inhibitor

Ruxolitinib Cream for Eczema (TRuE-AD4 Trial)

Phase 3
Recruiting
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to weeks 2, 4, 8, 12, 16, 20 and 24
Awards & highlights

Summary

This trial aims to determine how effective ruxolitinib cream is for people with moderate atopic dermatitis who did not respond well to or cannot tolerate topical corticosteroids or calcineur

Who is the study for?
Adults over 18 with moderate atopic dermatitis (AD) covering 10-20% of their body, not including the scalp. They must have had AD for at least two years and not responded well to or can't use topical steroids and calcineurin inhibitors. Participants need an IGA score of 3, EASI score above 7, significant itchiness, and a DLQI score over 10.Check my eligibility
What is being tested?
The trial is testing Ruxolitinib Cream against a placebo cream (Vehicle Cream) in adults with moderate AD who haven't seen improvement from standard treatments like topical steroids or are unable to use them due to intolerance or contraindications.See study design
What are the potential side effects?
Possible side effects of Ruxolitinib Cream may include application site reactions such as burning or irritation, headaches, increased risk of infections due to immune system effects, and possibly other skin issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to weeks 2, 4, 8, 12, 16, 20 and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to weeks 2, 4, 8, 12, 16, 20 and 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
VC Period: Proportion of participants who achieved Investigator's Global Assessment Treatment Success (IGA-TS)
Secondary outcome measures
VC Period: Change from baseline (pre-study cream application) in current Itch NRS score at 5, 15, 30, 45, and 60 minutes and 2, 4, and 6 hours post-initial dose on Day 1.
VC Period: Number of Treatment Emergent Adverse Events (TEAEs)
VC Period: Proportion of participants achieving at least a 2-point decrease from baseline in current Itch NRS score at 5, 15, 30, 45, and 60 minutes and 2, 4, and 6 hours post-initial dose on Day 1.
+29 more

Side effects data

From 2020 Phase 3 trial • 631 Patients • NCT03745638
9%
Upper respiratory tract infection
6%
Nasopharyngitis
4%
Headache
1%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ruxolitinib 0.75% Cream BID
Vehicle Cream BID
Ruxolitinib 1.5% Cream BID

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: VC Period: Ruxolitinib 1.5% Cream BIDExperimental Treatment1 Intervention
Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Group II: VC Extension Period: Ruxolitinib 1.5% cream open-label escape armExperimental Treatment1 Intervention
Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Group III: VC Extension Period/Escape Arm: Ruxolitinib 1.5% Cream BIDExperimental Treatment1 Intervention
Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 24 during the Vehicle Control Extension (VCE) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
Group IV: VC Period: Vehicle Cream BIDPlacebo Group1 Intervention
Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Group V: VC Extension Period/Escape Arm: Vehicle Cream BIDPlacebo Group1 Intervention
Participants who applied vehicle cream during the VC Period, continued applying vehicle cream as a thin film twice daily (BID) from Weeks 8 to 24 during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved. Participants will be eligible to enter the ruxolitinib 1.5% cream open-label escape arm as defined in the protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib Cream
2018
Completed Phase 3
~640

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
373 Previous Clinical Trials
55,554 Total Patients Enrolled
Incyte Medical MonitorStudy DirectorIncyte Corporation
26 Previous Clinical Trials
5,128 Total Patients Enrolled
~150 spots leftby Aug 2025